Asia Pacific Intravenous Immunoglobulin Market Size & Outlook
Asia Pacific intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Asia Pacific intravenous immunoglobulin market highlights
- The Asia Pacific intravenous immunoglobulin market generated a revenue of USD 3,224.5 million in 2024.
- The market is expected to grow at a CAGR of 8.2% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 3,224.5 million |
| Market revenue in 2030 | USD 5,201.7 million |
| Growth rate | 8.2% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.3% of the global intravenous immunoglobulin market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,201.7 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 21.19% in 2024. Horizon Databook has segmented the Asia Pacific intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The IVIG market in the Asia Pacific region is expanding rapidly, driven by a significant increase in the incidence of immunodeficiency diseases, particularly in countries such as China, India, Japan, and Australia. The growing need for IVIG therapies to treat conditions such as CIDP, Myasthenia Gravis, and Guillain-Barre Syndrome is evident, with hospital pharmacies and specialty pharmacies being the main distributors.
Companies like CSL, China Biologics Products Inc., and Kedrion are working to establish a stronger foothold in the region by increasing the availability of their therapies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific intravenous immunoglobulin market size, by country, 2018-2030 (US$M)
Asia Pacific Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
